Related references
Note: Only part of the references are listed.FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Aviva C. Krauss et al.
CLINICAL CANCER RESEARCH (2019)
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Dongfen Yuan et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil(A (R)) or Caelyx(A (R)) in advanced ovarian cancer
Shravanti Bhowmik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
Evan C. Chen et al.
ONCOTARGETS AND THERAPY (2018)
Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
Jimin Zhang et al.
FRONTIERS IN MICROBIOLOGY (2018)
Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks
Evan P. Troendle et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1
Joshua F. Apgar et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
Min Li et al.
AAPS JOURNAL (2017)
Overcoming key biological barriers to cancer drug delivery and efficacy
Susy M. Kim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Liposomal Formulations in Clinical Use: An Updated Review
Upendra Bulbake et al.
PHARMACEUTICS (2017)
Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors
Tarun Ojha et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models
Vinod Burade et al.
BMC CANCER (2017)
Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus CaelyxA® (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats
Vinod Burade et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Neil R. H. Stone et al.
DRUGS (2016)
Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model
Judith A. Smith et al.
GYNECOLOGIC ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Phatsapong Yingchoncharoen et al.
PHARMACOLOGICAL REVIEWS (2016)
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
Hiroshi Maeda
ADVANCED DRUG DELIVERY REVIEWS (2015)
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
T. C. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development: A Pharmaceutical Industry Perspective
H. M. Jones et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents
Andrew T. Lucas et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
Huali Wu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Iftikhar Ali Khawar et al.
JOURNAL OF CONTROLLED RELEASE (2015)
The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation
Shawn Stapleton et al.
JOURNAL OF CONTROLLED RELEASE (2015)
A Pharmacokinetic Model for Quantifying the Effect of Vascular Permeability on the Choice of Drug Carrier: A Framework for Personalized Nanomedicine
Ameya R. Kirtane et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles
Louis T. Curtis et al.
PLOS ONE (2015)
Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors
Triantafyllos Stylianopoulos et al.
ANNALS OF BIOMEDICAL ENGINEERING (2015)
Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy
V. Sinha et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition
Leonid Kagan et al.
PHARMACEUTICAL RESEARCH (2014)
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
Sihem Ait-Oudhia et al.
Pharmaceutics (2014)
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
Hiroshi Maeda et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Cationic Nanoparticles Have Superior Transvascular Flux into Solid Tumors: Insights from a Mathematical Model
Triantafyllos Stylianopoulos et al.
ANNALS OF BIOMEDICAL ENGINEERING (2013)
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
Huali Wu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes
Shawn Stapleton et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles
Mark J. Ernsting et al.
JOURNAL OF CONTROLLED RELEASE (2013)
The Utility of Modeling and Simulation in Drug Development and Regulatory Review
Shiew-Mei Huang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
A Computational Model for Predicting Nanoparticle Accumulation in Tumor Vasculature
Hermann B. Frieboes et al.
PLOS ONE (2013)
A Mathematical Model of the Enhanced Permeability and Retention Effect for Liposome Transport in Solid Tumors
Shawn Stapleton et al.
PLOS ONE (2013)
Combining two strategies to improve perfusion and drug delivery in solid tumors
Triantafyllos Stylianopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
A. Gregory Sorensen et al.
CANCER RESEARCH (2012)
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
William C. Zamboni et al.
CLINICAL CANCER RESEARCH (2012)
Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes
Xiaoming Xu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
Huali Wu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Twan Lammers et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Endocytosis and Intracellular Trafficking as Gateways for Nanomedicine Delivery: Opportunities and Challenges
Ruth Duncan et al.
MOLECULAR PHARMACEUTICS (2012)
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
Vikash P. Chauhan et al.
NATURE NANOTECHNOLOGY (2012)
Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug-Specific Parameters in Local Delivery to Tumors
B. S. Hendriks et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2012)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes
B. J. Crielaard et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Allometric scaling of pegylated liposomal anticancer drugs
Whitney P. Caron et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2011)
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Vikash P. Chauhan et al.
ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING, VOL 2 (2011)
Delivery of siRNA Therapeutics: Barriers and Carriers
Jie Wang et al.
AAPS JOURNAL (2010)
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Mingguang Lu et al.
ACS NANO (2010)
High-Dose Bupivacaine Remotely Loaded into Multivesicular Liposomes Demonstrates Slow Drug Release Without Systemic Toxic Plasma Concentrations After Subcutaneous Administration in Humans
Elyad M. Davidson et al.
ANESTHESIA AND ANALGESIA (2010)
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Rao N. V. S. Mamidi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Doxorubicin Cardiomyopathy
Kanu Chatterjee et al.
CARDIOLOGY (2010)
Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL)
S. M. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
Wah-Seng Lim et al.
LEUKEMIA RESEARCH (2010)
Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients With Refractory Aggressive Non-Hodgkin Lymphoma Report of the Pivotal Phase 2 Study
M. A. Rodriguez et al.
CANCER (2009)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
Multiscale modelling and nonlinear simulation of vascular tumour growth
Paul Macklin et al.
JOURNAL OF MATHEMATICAL BIOLOGY (2009)
Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors
Hemant Sarin et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
Paul Tardi et al.
LEUKEMIA RESEARCH (2009)
Amphotericin B: side effects and toxicity
Rafael Laniado-Laborin et al.
REVISTA IBEROAMERICANA DE MICOLOGIA (2009)
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
Patrick A. Bovier
EXPERT REVIEW OF VACCINES (2008)
Pharmacokinetics and In Vivo Drug Release Rates in Liposomal Nanocarrier Development
Daryl C. Drummond et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Cardiac safety of liposomal anthracyclines
Gerald Batist
CARDIOVASCULAR TOXICOLOGY (2007)
A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt (R)) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study
Surasak Phuphanich et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
Dmitri B. Kirpotin et al.
CANCER RESEARCH (2006)
Liposomal muramyl tripeptide phosphatidylethanolamine:: Targeting and activating macrophages for adjuvant treatment of osteosarcoma
A Nardin et al.
CURRENT CANCER DRUG TARGETS (2006)
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector
TD McKee et al.
CANCER RESEARCH (2006)
Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors
KM Laginha et al.
CLINICAL CANCER RESEARCH (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors:: an open-label, single-dose study
K Mross et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Advantages of liposomal delivery systems for anthracyclines
TM Allen et al.
SEMINARS IN ONCOLOGY (2004)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems
JA Shabbits et al.
JOURNAL OF CONTROLLED RELEASE (2002)
Liposome clearance
T Ishida et al.
BIOSCIENCE REPORTS (2002)
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
I Bekersky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Clinical pharmacokinetics of cytarabine formulations
A Hamada et al.
CLINICAL PHARMACOKINETICS (2002)
Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models
A Gabizon et al.
JOURNAL OF DRUG TARGETING (2002)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma
L Fumagalli et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Openings between defective endothelial cells explain tumor vessel leakiness
H Hashizume et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
